G.d. Searle & Company

Pfizer Corporation

Pharmacia Corporation

Monsanto Company

Sugen Incorporated

Jaime L Masferrer

Gary B Gordon

John Patrick McKearn

Stephen T Gately

James J Cunningham

Alane T Koki

John Jeffrey Talley

Len F Lee

Karen Seibert

Bryan Hurst Norman

Todd M Maddux

Luka Milas

Mathew J Graneto

Parul Doshi

Julie Cherrington

Amiram Raz

Bryan H Norman

The invention relates to the compounds of formula (I): or a pharmaceutically acceptable salt and solvate thereof, wherein Ris F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular allergic and respiratory diseases, disorders and conditions.

Pyrazole analogs

The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors of the formula I: wherein R, R, R, R, R, R, and Rare defined herein, in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.

Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent

A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.

Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.

Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.

Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.

Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating angiogenic disorders.

Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I. ##STR1## wherein A, R.sup.2 and R.sup.3 are as described in the specification.

Method of using cyclooxygenase-2 inhibitors in the treatment and

Substituted oxazolyl compounds for the treatment of inflammation

2-Substituted-4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)oxazoles or 2-substituted-5-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)oxazoles and derivatives thereof are found to posses significant antiinflammatory activity, especially useful for the treatment of arthritis without deleterious side effects.

Growing community of inventors

Chesterfield, MO, United States of America

Jaime L Masferrer